Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations

被引:1
作者
Zhu, Yanyan [1 ]
Jean-Baptiste, Milenka [2 ]
Lenderking, William R. R. [2 ,3 ,5 ]
Bell, Jill A. A. [1 ]
Revicki, Dennis A. A. [2 ]
Lin, Huamao M. M. [1 ]
Brake, Rachael [1 ]
Reeve, Bryce B. B. [1 ,4 ]
机构
[1] Takeda Pharmaceut Co Ltd, Millennium Pharmaceut Inc, Cambridge, MA USA
[2] Evidera Inc, Bethesda, MD USA
[3] Evidera Inc, Waltham, MA USA
[4] Duke Univ, Sch Med, Durham, NC USA
[5] Evidera Inc, 7101 Wisconsin Ave, Suite 1400, Bethesda, MD 20851 USA
来源
CANCER MEDICINE | 2023年 / 12卷 / 05期
关键词
adverse events; non-small cell lung cancer; oncology; patient-reported outcome measures; PRO-CTCAE; symptoms; tolerability; CONTENT VALIDITY; PRO INSTRUMENTS; CLINICAL-TRIALS; QLQ-C30;
D O I
10.1002/cam4.5376
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Tolerability and safety of treatments are important in oncology trials and should be informed by patient assessments. We identified the most relevant patient-reported symptomatic adverse events (AEs) to measure in patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Methods: This study selected relevant symptomatic AEs from 78 AEs available in the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) measurement system. Initially, symptomatic AEs were selected based on literature and product labeling reviews, and then core sets of symptomatic AEs were identified by patient and clinician interviews. Qualitative and descriptive analyses were performed using the data collected from three iterative rounds of patient interviews. Results: During concept elicitation interviews involving 29 patients, 12 symptomatic AEs were identified and were then adapted into a 25-item PRO-CTCAE form for use in future clinical trials along with commonly used PRO measures. Cognitive interviews showed that the PRO-CTCAE items were easy to answer and appropriate for assessing the patients' experience with symptomatic AEs. This study also assessed disease symptoms, impacts, and overall patient experience. Conclusions: The 25-item PRO-CTCAE form captures the most relevant symptomatic AEs in this patient population, and it is available for future studies. Baseline characterization of AEs associated with this distinct patient group contributes to our broader knowledge about NSCLC and through platforms like Project Patient Voice will expand our understanding of treatment tolerability and safety for NSCLC. Ultimately, this data collection will help inform decision-making for patients, caregivers, healthcare providers, and regulators.
引用
收藏
页码:5494 / 5505
页数:12
相关论文
共 28 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics [J].
Arcila, Maria E. ;
Nafa, Khedoudja ;
Chaft, Jamie E. ;
Rekhtman, Natasha ;
Lau, Christopher ;
Reva, Boris A. ;
Zakowski, Maureen F. ;
Kris, Mark G. ;
Ladanyi, Marc .
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) :220-229
[3]   Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [J].
Basch, Ethan ;
Reeve, Bryce B. ;
Mitchell, Sandra A. ;
Clauser, Steven B. ;
Minasian, Lori M. ;
Dueck, Amylou C. ;
Mendoza, Tito R. ;
Hay, Jennifer ;
Atkinson, Thomas M. ;
Abernethy, Amy P. ;
Bruner, Deborah W. ;
Cleeland, Charles S. ;
Sloan, Jeff A. ;
Chilukuri, Ram ;
Baumgartner, Paul ;
Denicoff, Andrea ;
St Germain, Diane ;
O'Mara, Ann M. ;
Chen, Alice ;
Kelaghan, Joseph ;
Bennett, Antonia V. ;
Sit, Laura ;
Rogak, Lauren ;
Barz, Allison ;
Paul, Diane B. ;
Schrag, Deborah .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (09)
[4]   THE EORTC QLQ-LC13 - A MODULAR SUPPLEMENT TO THE EORTC CORE QUALITY-OF-LIFE QUESTIONNAIRE (QLQ-C30) FOR USE IN LUNG-CANCER CLINICAL-TRIALS [J].
BERGMAN, B ;
AARONSON, NK ;
AHMEDZAI, S ;
KAASA, S ;
SULLIVAN, M .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (05) :635-642
[5]   Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review [J].
Burnett, Heather ;
Emich, Helena ;
Carroll, Chris ;
Stapleton, Naomi ;
Mahadevia, Parthiv ;
Li, Tracy .
PLOS ONE, 2021, 16 (03)
[6]   The Symptom Burden of Cancer: Evidence for a Core Set of Cancer-Related and Treatment-Related Symptoms From the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns Study [J].
Cleeland, Charles S. ;
Zhao, Fengmin ;
Chang, Victor T. ;
Sloan, Jeff A. ;
O'Mara, Ann M. ;
Gilman, Paul B. ;
Weiss, Matthias ;
Mendoza, Tito R. ;
Lee, Ju-Whei ;
Fisch, Michael J. .
CANCER, 2013, 119 (24) :4333-4340
[7]   Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [J].
Dueck, Amylou C. ;
Mendoza, Tito R. ;
Mitchell, Sandra A. ;
Reeve, Bryce B. ;
Castro, Kathleen M. ;
Rogak, Lauren J. ;
Atkinson, Thomas M. ;
Bennett, Antonia V. ;
Denicoff, Andrea M. ;
O'Mara, Ann M. ;
Li, Yuelin ;
Clauser, Steven B. ;
Bryant, Donna M. ;
Bearden, James D., III ;
Gillis, Theresa A. ;
Harness, Jay K. ;
Siegel, Robert D. ;
Paul, Diane B. ;
Cleeland, Charles S. ;
Schrag, Deborah ;
Sloan, Jeff A. ;
Abernethy, Amy P. ;
Bruner, Deborah W. ;
Minasian, Lori M. ;
Basch, Ethan .
JAMA ONCOLOGY, 2015, 1 (08) :1051-1059
[8]   EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer [J].
Fang, Wenfeng ;
Huang, Yihua ;
Hong, Shaodong ;
Zhang, Zhonghan ;
Wang, Minghui ;
Gan, Jiadi ;
Wang, Wenjing ;
Guo, Honglin ;
Wang, Kai ;
Zhang, Li .
BMC CANCER, 2019, 19 (1)
[9]  
Food and Drug Administration (FDA),, 2020, PROJ PAT VOIC
[10]  
FRIESE S., 2013, ATLAS. ti 7 user guide and reference